GeneDx (WGS) to Release Quarterly Earnings on Tuesday

GeneDx (NASDAQ:WGS) is expected to be posting its quarterly earnings results before the market opens on Tuesday, February 18th. Analysts expect GeneDx to post earnings of $0.04 per share and revenue of $82.24 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

GeneDx Stock Performance

WGS opened at $68.15 on Tuesday. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. GeneDx has a 12-month low of $3.86 and a 12-month high of $98.87. The business has a 50 day moving average of $76.76 and a 200-day moving average of $59.75. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -21.91 and a beta of 2.01.

Insider Buying and Selling

In other news, CFO Kevin Feeley sold 35,506 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $93.82, for a total transaction of $3,331,172.92. Following the sale, the chief financial officer now directly owns 2,472 shares of the company’s stock, valued at approximately $231,923.04. This represents a 93.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Katherine Stueland sold 1,657 shares of the business’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $78.48, for a total value of $130,041.36. Following the completion of the transaction, the chief executive officer now directly owns 3,937 shares of the company’s stock, valued at approximately $308,975.76. This trade represents a 29.62 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 363,669 shares of company stock valued at $28,061,081. 27.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have issued reports on WGS. Wells Fargo & Company raised their price target on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, October 30th. TD Cowen lifted their target price on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday, January 7th. Craig Hallum increased their price target on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Finally, The Goldman Sachs Group raised their price objective on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $70.67.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.